Methods Used for Trend Estimation of Epidemiological Figures in the German Benefit Assessment (AMNOG) Process

被引：0
|
作者：
Schnaidt, S. [1 ]
Seidel, K. [1 ]
Viering, T. [1 ]
Loepmeier, J. F. [1 ]
Borchert, K. [1 ]
Jacob, C. [1 ]
机构：
[1] Xcenda GmbH, Hannover, NJ, Germany
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA203
引用
收藏
页码：S336 / S336
页数：1
相关论文
共 23 条
  • [1] THE RELEVANCE OF REAL WORLD EVIDENCE STUDIES IN THE GERMAN BENEFIT ASSESSMENT (AMNOG) PROCESS
    Borchert, K.
    Loepmeier, J. F.
    Braun, S.
    Jacob, C.
    [J]. VALUE IN HEALTH, 2019, 22 : S795 - S795
  • [2] RELEVANCE OF INDIRECT COMPARISONS IN THE GERMAN EARLY BENEFIT ASSESSMENT (AMNOG)
    Lebioda, A.
    Gasche, D.
    Dippel, F. W.
    Plantoer, S.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A484 - A485
  • [3] 10 YEARS OF AMNOG: IMPORTANCE OF REAL-WORLD EVIDENCE STUDIES IN THE GERMAN BENEFIT ASSESSMENT PROCESS
    Seidel, K.
    Schnaidt, S.
    Viering, T.
    Loepmeier, J. F.
    Borchert, K.
    Jacob, C.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S314 - S314
  • [4] GERMAN AMNOG BENEFIT ASSESSMENT: THE TYPE OF APPROPRIATE COMPARATOR MAKES THE DIFFERENCE
    Templin, C.
    Billig, S.
    Damen, D.
    Kulp, W.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A461 - A462
  • [5] TRENDS IN THE RELEVANCE OF REAL WORLD EVIDENCE STUDIES IN THE GERMAN BENEFIT ASSESSMENT (AMNOG) PROCESS 2011-2019
    Borchert, K.
    Seidel, K.
    Loepmeier, J. F.
    Braun, S.
    Jacob, C.
    [J]. VALUE IN HEALTH, 2020, 23 : S666 - S666
  • [6] OVERVIEW OF GERMAN AMNOG DOSSIERS WITH PRICE ANALYSIS BEFORE AND AFTER EARLY BENEFIT ASSESSMENT
    Bonduelle, D.
    Batscheider, A.
    Tremmel, M.
    Antoni, B.
    Bocuk, D.
    Roxlau, T.
    Mihaylova, E.
    [J]. VALUE IN HEALTH, 2018, 21 : S190 - S190
  • [7] Benefit Assessment and Price Negotiation Under AMNOG: Calculable Process or Unfair Poker Game?
    Radic, D.
    Haugk, S.
    Radic, M.
    [J]. GESUNDHEITSWESEN, 2018, 80 (06) : 573 - 579
  • [8] IMPORTANCE OF HEALTH-RELATED QUALITY OF LIFE AS AN ENDPOINT IN BENEFIT ASSESSMENT ACCORDING TO THE GERMAN AMNOG
    Koester, C.
    Kossmann, B.
    Boehm, K.
    Wasem, J.
    Aidelsburger, P.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A310 - A310
  • [9] DATA SOURCES USED TO DETERMINE THE TARGET POPULATION SIZE FOR ORPHAN DRUGS - A REVIEW OF GERMAN AMNOG BENEFIT ASSESSMENTS
    Schneider, K. M.
    Seidel, K.
    Roehrkaste, J.
    Braun, S.
    [J]. VALUE IN HEALTH, 2019, 22 : S856 - S856
  • [10] THE GERMAN AMNOG DRUG REIMBURSEMENT PROCESS: FACTORS ASSOCIATED WITH GBA-DECISIONS ABOUT THE ADDITIONAL BENEFIT
    Mueller, S.
    Brandt, S.
    Wilke, T.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A546 - A546
123